Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis
Status:
Recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
Multiple Sclerosis (MS) is the most frequent cause of non-traumatic disability in people
under 55 years of age. Fatigue is the most frequent and disabling symptom in the disease, and
for which there is no effective treatment. Among the proposed drugs, amantadine is the one
that could be most useful, although up to now it has not been adequately demonstrated due to
a lack of sufficiently powerful and methodologically appropriate clinical trials.
Transcranial magnetic stimulation (TMS) has recently been proposed as a useful treatment for
fatigue in MS in preliminary studies.